Penumbra, Inc. (PEN)

Market Cap	9.31B
Revenue (ttm)	1.16B
Net Income (ttm)	34.55M
Shares Out	38.38M
EPS (ttm)	0.89
PE Ratio	273.90
Forward PE	67.56
Dividend	n/a
Ex-Dividend Date	n/a

Volume	438,785
Open	242.00
Previous Close	243.52
Day's Range	241.27 - 245.56
52-Week Range	148.00 - 277.34
Beta	0.52
Analysts	Buy
Price Target	259.86 (+7.14%)
Earnings Date	Oct 30, 2024

About PEN

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, S...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Sep 18, 2015
• Employees: 4,200
• Stock Exchange: NYSE
• Ticker Symbol: PEN
• Website: https://www.penumbrainc.com

Analyst Forecast

According to 15 analysts, the average rating for PEN stock is "Buy." The 12-month stock price forecast is $259.86, which is an increase of 7.14% from the latest price.

Price Target

$259.86

(7.14% upside)

Analyst Consensus: Buy